GNLX
Genelux Corporation
NASDAQ
Listed Jan 26, 2023
Healthcare
· Biotechnology
· US
·
genelux.com
52w Low $2.29
8.6% of range
52w High $8.54
50d MA $2.65
200d MA $3.80
P/E (TTM)
-3.2x
EV/EBITDA
-4.9x
P/B
8.8x
Debt/Equity
0.1x
ROE
-278.5%
P/FCF
-6.1x
RSI (14)
—
ATR (14)
—
Beta
0.46
50d MA
$2.65
200d MA
$3.80
Avg Volume
196.4K
About
Recent Earnings
Recent Analyst Ratings
Insider Trades
Recent Filings
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
2625 Townsgate Road · Westlake Village, CA 91361 · US
Date
Time
Est
Rptd
Surp
Base
Gap%
D1%
D2%
D3%
D4%
D5%
Guide ▲★
Mar 19, 2026
AMC
-0.22
-0.24
-9.1%
2.54
-5.5%
-5.5%
+3.3%
-2.4%
+9.5%
-0.8%
—
Nov 5, 2025
AMC
-0.23
-0.21
+8.7%
7.84
-4.3%
-32.4%
+2.3%
+8.7%
+1.5%
-0.8%
—
Aug 7, 2025
AMC
-0.22
-0.20
+9.1%
3.34
+6.6%
-5.7%
+4.1%
-2.7%
+0.3%
+6.6%
—
May 6, 2025
AMC
-0.24
-0.21
+12.5%
2.33
+2.6%
-0.4%
+22.8%
+3.9%
-6.1%
-10.8%
—
Mar 28, 2025
AMC
-0.17
-0.26
-52.9%
3.08
-2.6%
-12.3%
-3.7%
-2.3%
-1.6%
-4.4%
—
Nov 14, 2024
AMC
-0.19
-0.19
+0.0%
2.94
+0.0%
-19.7%
+11.4%
-5.7%
+0.4%
-1.2%
—
Aug 14, 2024
AMC
-0.19
-0.22
-15.8%
2.09
+4.3%
+1.9%
-5.2%
+3.5%
-2.4%
+0.5%
—
May 9, 2024
AMC
-0.23
-0.29
-26.1%
4.02
-1.5%
-4.7%
-5.7%
-0.8%
+1.7%
-1.1%
—
Mar 29, 2024
AMC
-0.21
-0.25
-19.0%
—
—
—
—
—
—
—
—
Nov 14, 2023
AMC
-0.12
-0.20
-66.7%
14.59
-3.4%
-7.6%
-2.7%
-9.5%
-9.7%
-3.2%
—
Aug 14, 2023
AMC
-0.15
-0.23
-53.3%
22.87
+3.3%
+6.0%
-1.4%
-1.8%
+2.2%
-6.8%
—
May 15, 2023
AMC
-0.16
-0.53
-230.9%
23.19
-0.8%
+9.5%
-2.8%
+3.2%
+3.5%
-4.9%
—
Show 2 more
Date
Firm
Action
Grade
Target
Base
Open
Gap%
D1%
D2%
D3%
D4%
D5%
Mar 20
Benchmark
Maintains
Speculative Buy → Speculative Buy
—
$2.54
$2.40
-5.5%
-5.5%
+3.3%
-2.4%
+9.5%
-0.8%
May 8
Benchmark
Maintains
Speculative Buy → Speculative Buy
—
$2.32
$2.35
+1.3%
+22.8%
+3.9%
-6.1%
-10.8%
-3.2%
Mar 31
HC Wainwright & Co.
Maintains
Buy → Buy
—
$3.08
$3.00
-2.6%
-12.3%
-3.7%
-2.3%
-1.6%
-4.4%
Mar 25
HC Wainwright & Co.
Maintains
Buy → Buy
—
$3.89
$3.50
-10.0%
-12.6%
-5.9%
-5.3%
+1.7%
-12.3%
Nov 15
HC Wainwright & Co.
Maintains
Buy → Buy
—
$2.94
$2.94
+0.0%
-19.7%
+11.4%
-5.7%
+0.4%
-1.2%
Aug 15
HC Wainwright & Co.
Maintains
Buy → Buy
—
$2.09
$2.18
+4.3%
+1.9%
-5.2%
+3.5%
-2.4%
+0.5%
Jun 3
Benchmark
Maintains
Speculative Buy → Speculative Buy
—
$2.71
$2.75
+1.5%
+3.7%
-8.5%
+0.8%
-2.7%
-9.5%
May 31
Benchmark
Maintains
Speculative Buy → Speculative Buy
—
$2.65
$2.70
+1.9%
+2.3%
+3.7%
-8.5%
+0.8%
-2.7%
May 13
HC Wainwright & Co.
Maintains
Buy → Buy
—
$3.83
$3.89
+1.6%
-5.7%
-0.8%
+1.7%
-1.1%
+1.4%
Apr 3
Benchmark
Maintains
Speculative Buy → Speculative Buy
—
$5.25
$5.25
+0.0%
-7.4%
-2.7%
+4.2%
-5.3%
-1.5%
Apr 2
HC Wainwright & Co.
Maintains
Buy → Buy
—
$5.24
$5.19
-1.0%
+0.2%
-7.4%
-2.7%
+4.2%
-5.3%
Nov 24
Benchmark
Maintains
Speculative Buy → Speculative Buy
—
$11.19
$11.29
+0.9%
-0.8%
-2.1%
-3.8%
+11.9%
+1.7%
Jun 9
Benchmark
Maintains
Speculative Buy → Speculative Buy
—
$28.40
$28.98
+2.0%
-2.0%
+7.6%
+6.8%
+6.4%
+6.2%
May 18
Brookline Capital
Maintains
Hold → Hold
—
$24.70
$24.48
-0.9%
+3.2%
+3.5%
-4.9%
-3.5%
-3.9%
Feb 15
Benchmark
Maintains
Speculative Buy → Buy
—
$5.99
$6.01
+0.3%
+7.6%
-3.8%
+6.0%
+13.3%
+16.7%
Show 5 more
Date
Insider
Title
Type
Shares
Price
Value
Owned After
D1%
D5%
May 11, 2026
Zindrick ThomasOff
President and CEO
Sell
2,798
$2.94
$8K
532,051
+7.41%
—
May 11, 2026
Cappello JosephOff
Chief Technical Officer
Sell
605
$2.97
$2K
154,549
+7.41%
—
May 11, 2026
Smalling RalphOff
Head of Regulatory
Sell
270
$2.98
$804
67,803
+7.41%
—
May 11, 2026
Yu YongOff
Chief Scientific Officer
Sell
605
$2.97
$2K
149,706
+7.41%
—
Data updated apr 25, 2026 11:51am
· Source: massive.com